Gene Therapy Insurance Coverage
Gene Therapy Insurance Coverage
Gene Therapy Costs Millions. Getting Insurance to Cover It Is a Different Battle Entirely.
6 minute read
Casgevy, the first CRISPR-based gene therapy, received FDA approval in late 2023 for sickle cell disease and transfusion-dependent beta-thalassemia. Hemgenix, for hemophilia B, carries a list price of approximately $3.5 million per treatment. These are not theoretical price points. They are real costs that real patients are now facing as they pursue treatments that could, in some cases, be curative. The problem is that having an FDA-approved treatment and having insurance that will cover it are two very different things. If you or someone you care for is pursuing gene therapy, understanding the coverage landscape before you start the process can make the difference between access and a denial that feels impossible to overcome.
The Coverage Gap for Gene Therapies
FDA approval does not guarantee insurance coverage. This is true for many drugs, but it is especially pronounced for gene therapies for several reasons.
Gene therapies are typically one-time treatments. The clinical data supporting them comes from relatively small trials because the patient populations are small. The treatments are administered at specialized centers with specific expertise requirements. And the price points are unlike anything most insurance plans have underwritten before.
As of 2026, coverage for gene therapies like Casgevy and Hemgenix varies significantly across payers. Some large commercial insurers have developed coverage policies that include FDA-approved gene therapies for their labeled indications. Others have issued coverage policies that apply strict clinical criteria, require pre-authorization from a specialized review team, or include language that effectively limits access to patients who meet very narrow criteria that may not match your actual clinical picture.
Medicaid coverage varies by state. Some state Medicaid programs have developed specific coverage pathways for high-cost gene therapies. Others have been slower to act, and for Medicaid patients who might benefit from Casgevy for sickle cell disease, this variation in state-level coverage creates an uneven landscape.¹
The Muscular Dystrophy Association's gene therapy insurance guide notes that patients pursuing gene therapy frequently face prior authorization requirements, requests for extensive documentation, and in some cases, denials that cite the treatment as investigational or experimental even when FDA approval has been granted.²
What "Experimental" Means in an Insurance Denial, and Why It Is Often Wrong
When an insurer denies a gene therapy claim, one of the most common denial reasons you will see is language like "experimental," "investigational," or "not medically necessary for this indication." It is important to understand what these terms mean in the context of insurance coverage, because the legal and clinical definitions are not the same.
From a legal standpoint, most insurance contracts define "experimental or investigational" treatments as those that lack sufficient clinical evidence of effectiveness, are under active clinical trial, or have not received regulatory approval for the condition being treated. Once an FDA approval has been granted for a specific indication, a denial based on "experimental" language for that same indication is legally questionable and, in many cases, can be successfully appealed.
If your insurer denied a gene therapy as "experimental" and the treatment has FDA approval for your specific diagnosis, that denial is potentially overturnable. The FDA approval record is public and citable. Your physician's documentation connecting your diagnosis to the approved indication is critical supporting evidence for your appeal.
The standard of review that most state insurance regulations require for investigational denials involves comparing the treatment to what is accepted in the relevant medical community. Published clinical trial data, FDA approval, and endorsement or guidance from relevant specialty societies (such as the American Society of Hematology for sickle cell therapies) constitute that standard of medical community acceptance.
Coverage Criteria You Will Likely Face
Even when an insurer has a coverage policy for a gene therapy, the clinical criteria in that policy may be strict. For Casgevy and sickle cell disease, typical coverage criteria include confirmation of the diagnosis through genetic testing, documentation of disease severity meeting a certain threshold (often measured by frequency of vaso-occlusive crises), documentation of prior treatment history, and referral to or treatment at a certified treatment center.
Having all of this documentation organized before your insurer's prior authorization process begins is the most important thing you can do to improve your chances of approval on the first submission.
Work with your care team to compile a clinical summary that addresses each element of the coverage criteria specifically. If your insurer's policy requires documentation of a minimum number of pain crises per year and you have that documentation in your medical records, make sure it is explicitly cited in the prior authorization request, not buried in chart notes.
What This Means for You
If you are pursuing gene therapy, treat the insurance coverage process as a parallel workstream to your clinical preparation. Do not assume that FDA approval means your insurer will say yes.
Request your insurer's coverage policy for the specific gene therapy you are pursuing. This is a public document and your plan is required to provide it. Read the clinical criteria carefully and compare them to your medical history.
Ask your treating physician to write a letter of medical necessity that addresses each coverage criterion directly and cites relevant clinical evidence and the FDA approval record.
If your initial prior authorization is denied, file an appeal immediately. Request an expedited appeal if your clinical situation is time-sensitive. At the appeal stage, you have the right to request an external independent review, which brings your case before a reviewer who is not employed by or financially connected to your insurer.
Ellen can help you understand your denial and build your appeal. Start here
Frequently Asked Questions
Does FDA approval mean my insurance has to cover a gene therapy?
FDA approval is strong evidence that a treatment is not experimental or investigational, but it does not automatically require your insurer to cover it. Most insurance contracts give plans discretion to establish their own coverage criteria for specific treatments. However, if your insurer denies a gene therapy that has FDA approval for your diagnosed condition as "experimental," that denial is likely appealable.
What is a letter of medical necessity and why does it matter for gene therapy?
A letter of medical necessity is a document your physician writes to your insurer explaining why a specific treatment is medically required for your individual situation. For gene therapy, this letter should connect your diagnosis to the FDA-approved indication, summarize your clinical history and disease severity, explain why you meet the insurer's coverage criteria, and address any language the insurer uses as a basis for denial. A specific, well-documented letter is significantly more persuasive than a general statement.
What if I am on Medicaid and want to access Casgevy?
Medicaid coverage for gene therapies varies by state. If your state Medicaid program has not issued a coverage policy for Casgevy, you can still pursue prior authorization and appeal a denial. Contact your state Medicaid agency directly and ask whether a coverage policy exists. Patient advocacy organizations focused on sickle cell disease can also be valuable resources for navigating state Medicaid coverage.
Sources: